Trial Profile

Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use

Most Recent Events

01 Apr 2021 Planned End Date changed from 1 Jul 2022 to 17 Oct 2018.
01 Apr 2021 Planned primary completion date changed from 1 Jul 2022 to 17 Oct 2018.
01 Oct 2018 Status changed to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com